Gland Pharma Q1 net surges 47% to ₹317 cr on higher revenue
Gland Pharma reported a 47% increase in net profit for the June quarter, reaching ₹317 crore, driven by strong demand and new product launches. The company also announced a strategic manufacturing partnership to expand its global footprint in sterile injectables.
Why it matters
The company's growth reflects the increasing global demand for contract manufacturing in the pharmaceutical sector, particularly for complex injectable products.
Injectable-focussed generic drugmaker Gland Pharma reported consolidated net profit for June quarter rose 47% year-on-year (YoY) to ₹317 crore.
It came on a 20% YoY increase in revenue from operations to ₹1,800.3 crore. On a sequential basis, net profit was 14% lower and revenue 3% higher.
Growth was driven by recent product launches from CDMO (Contract Development and Manufacturing Organization) portfolio and strong customer demand. The company is investing in differentiated technologies and capacity expansions as part of a focus on a developing a robust CDMO pipeline, Executive Chairman Srinivas Sadu said.
Revenue from its key U.S. market increased 32% YoY to ₹.981 crore, while remaining flat on a sequential basis. Revenue from Canada, Australia and New Zealand (other core markets) declined 28% YoY to ₹53.4 crore and 9% sequentially.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in